ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question

Roche’s Tecentriq made history last year as the first PD-1/L1 agent to win an approval in triple-negative breast cancer. But trials with seemingly contradictory results put its potential role in the hard-to-treat disease into question, especially as Merck & Co. makes inroads into the same field with its formidable Keytruda.